STAA

STAAR Surgical Company (STAA) | Rumor.io

STAAR Surgical

STAA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,584

Bullish sentiment (50-day avg)99%

Price to earnings ratio259.8

Market capitalization1B

Earnings per share0.08

Dividend yield (TTM)—

Revenue (annual)239.4M

Net income (annual)-80.4M

Social

What share of all stock conversation is about STAA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Sep 24

STAAR Surgical Company's phakic lenses, the global leader in ICL market, have seen a significant decline in US laser refractive surgery, down ~65% since 2000.
The company's stock has also declined, down ~85% in 5 years, despite being the market leader.
STAAR Surgical has authorized a $50M buyback and intends to fund it with organic free cash flow and cash on hand.

Generated by AI

Sentiment

Of the messages about STAA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +14.29	93.33% -5.91	79.7% +8.77
Bearish	0%	0% -14.29	6.67% +5.91	20.3% -8.77

Bullish· Apr 9

STAAR Surgical Company's ($STAA) Q1 revenue is expected to exceed $90 million, crushing the $67.6 million consensus estimate.
The company's strong Q1 sales beat is driven by a sharp rebound in China, following last year's inventory destocking by distributors.
Canaccord Genuity upgraded $STAA to Buy with a $27 price target, citing the company's improving profitability and strong cash flow generation.

Bearish· Feb 12

STAAR Surgical Company's Q4 results missed estimates, with a reported loss of $0.41 per share, $0.37 worse than the FactSet Consensus.
The company's outlook disappointed, and its stock price plummeted, with some analysts downgrading their target price to $17 from $45.
The company's dependence on the Chinese market, where sales have been declining, is a significant concern, with some predicting that it may take 6-8 months for the stock to recover to $20.

Generated by AI

Topics

Of the messages about STAA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	42.86%	46.67%	37.5%	62.86%
Macro	0%	13.33%	37.5%	7.26%
Analysts	28.57%	26.67%	16.67%	7.32%
Technical Analysis	14.29%	6.67%	4.17%	2.23%
Earnings	0%	0%	0%	17.34%
Controversies	14.29%	6.67%	4.17%	2.99%

Earnings· May 2

STAAR Surgical Company beats earnings per share (EPS) estimates by $0.08.
STAAR Surgical Company beats revenue estimates and raises its fiscal 2018 sales growth target to around 20% over 2017.
STAAR Surgical Company reports Q1 2018 earnings of $0.01 EPS, beating estimates.

Announcements· Apr 9

STAAR Surgical Company ($STAA) preannounced Q1 revenue above $90M, exceeding the $67.6M consensus.
The company's strong Q1 net sales were driven primarily by a sharp rebound in China, following last year's inventory destocking by distributors.
Canaccord Genuity upgraded $STAA to Buy with a $27 price target, citing the company's strong first quarter net sales and upside guidance for Q1.

Generated by AI

Community

Of the messages about STAA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	5.77%	7.63%	47.65%
Newcomers	100%	94.23%	92.37%	52.35%

Regulars· Apr 9

STAAR Surgical guides Q1 revenue well above consensus, exceeding $90 million, driven primarily by a sharp rebound in China.
The company's strong Q1 sales beat is attributed to a sharp rebound in China, following last year's inventory destocking by distributors, and improving profitability.
STAAR Surgical stock surges 18% on strong Q1 sales beat, with analysts upgrading their target prices and recommendations, citing momentum returning and improving visibility.

Newcomers· Sep 24

US laser refractive surgery has seen a significant decline since 2000, and STAAR Surgical has not been immune to this trend, with its stock price down ~85% in 5 years.
STAAR Surgical is the global leader in the market for phakic lenses, which are implanted in the eye to correct vision without removing the natural lens.
The company has recently authorized a $50M buyback, but details on this decision are not provided in the available information.

Generated by AI

News

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday | The Motley Fool

It was the subject of a recommendation upgrade from an analyst.

13h agoThe Motley Fool

STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know

15h agoYahoo Finance

STAAR Surgical Shares Rise After Stifel Upgrade

STAAR Surgical (STAA) shares rose 7% in Tuesday trading after Stifel upgraded the stock to buy from

17h agoYahoo Finance

STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside - Staar Surgical (NASDAQ

Stifel upgraded STAAR Surgical to Buy, while raising its price target, citing China momentum, EVO+ mix and upside to 2026-27 estimates.

20h agoBenzinga

Why is STAAR Surgical stock surging today?

21h agoInvesting.com

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Staar Surgical (NASDAQ:S

Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.

21h agoBenzinga

Also Discussed

Investors talking about STAA also mention

#	Name	Attention
1	Alcon Inc.ALC	0%0
2	SWAV - ShockWave Medical, Inc.	——
3	CONMED CorporationCNMD	0%new
4	Lineage Cell Therapeutics Inc.LCTX	0%-0.01
5	DALN - DallasNews Corporation	——
6	SP Funds S&P Global REIT Sharia ETFSPRE	0%0
7	SPDR DoubleLine Total Return Tactical ETFTOTL	0%new
8	SCMA - Seaport Calibre Materials Acquisition Corp.	——
9	BFIN - BankFinancial Corporation	——
10	AMEH - Apollo Medical Holdings, Inc.	——

STAAR Surgical Company

Healthcare
Medical Instruments & Supplies

STAAR Surgical Company is a medical technology company that designs, develops, manufactures, and markets implantable lenses for the eye and companion delivery systems. Its core product line includes Implantable Collamer® Lenses used in refractive surgery to address visual disorders such as myopia, hyperopia, astigmatism, and presbyopia. The company focuses on ophthalmic surgery solutions that are used by eye care professionals seeking lens-based vision correction options. STAAR Surgical also offers accessory systems that support lens implantation procedures and help deliver its products into the eye. Headquartered in Lake Forest, California, and founded in 1982, STAAR Surgical serves a global market centered on eye care and vision correction, with a business model built around specialized surgical devices and related procedure support.

Website

Location

25510 Commercentre Drive

Lake Forest, CA, 92630

United States

Social

What share of all stock conversation is about STAA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Sep 24

STAAR Surgical Company's phakic lenses, the global leader in ICL market, have seen a significant decline in US laser refractive surgery, down ~65% since 2000.
The company's stock has also declined, down ~85% in 5 years, despite being the market leader.
STAAR Surgical has authorized a $50M buyback and intends to fund it with organic free cash flow and cash on hand.

Generated by AI

Sentiment

Of the messages about STAA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +14.29	93.33% -5.91	79.7% +8.77
Bearish	0%	0% -14.29	6.67% +5.91	20.3% -8.77

Bullish· Apr 9

STAAR Surgical Company's ($STAA) Q1 revenue is expected to exceed $90 million, crushing the $67.6 million consensus estimate.
The company's strong Q1 sales beat is driven by a sharp rebound in China, following last year's inventory destocking by distributors.
Canaccord Genuity upgraded $STAA to Buy with a $27 price target, citing the company's improving profitability and strong cash flow generation.

Bearish· Feb 12

STAAR Surgical Company's Q4 results missed estimates, with a reported loss of $0.41 per share, $0.37 worse than the FactSet Consensus.
The company's outlook disappointed, and its stock price plummeted, with some analysts downgrading their target price to $17 from $45.
The company's dependence on the Chinese market, where sales have been declining, is a significant concern, with some predicting that it may take 6-8 months for the stock to recover to $20.

Generated by AI

Topics

Of the messages about STAA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	42.86%	46.67%	37.5%	62.86%
Macro	0%	13.33%	37.5%	7.26%
Analysts	28.57%	26.67%	16.67%	7.32%
Technical Analysis	14.29%	6.67%	4.17%	2.23%
Earnings	0%	0%	0%	17.34%
Controversies	14.29%	6.67%	4.17%	2.99%

Earnings· May 2

STAAR Surgical Company beats earnings per share (EPS) estimates by $0.08.
STAAR Surgical Company beats revenue estimates and raises its fiscal 2018 sales growth target to around 20% over 2017.
STAAR Surgical Company reports Q1 2018 earnings of $0.01 EPS, beating estimates.

Announcements· Apr 9

STAAR Surgical Company ($STAA) preannounced Q1 revenue above $90M, exceeding the $67.6M consensus.
The company's strong Q1 net sales were driven primarily by a sharp rebound in China, following last year's inventory destocking by distributors.
Canaccord Genuity upgraded $STAA to Buy with a $27 price target, citing the company's strong first quarter net sales and upside guidance for Q1.

Generated by AI

Community

Of the messages about STAA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	5.77%	7.63%	47.65%
Newcomers	100%	94.23%	92.37%	52.35%

Regulars· Apr 9

STAAR Surgical guides Q1 revenue well above consensus, exceeding $90 million, driven primarily by a sharp rebound in China.
The company's strong Q1 sales beat is attributed to a sharp rebound in China, following last year's inventory destocking by distributors, and improving profitability.
STAAR Surgical stock surges 18% on strong Q1 sales beat, with analysts upgrading their target prices and recommendations, citing momentum returning and improving visibility.

Newcomers· Sep 24

US laser refractive surgery has seen a significant decline since 2000, and STAAR Surgical has not been immune to this trend, with its stock price down ~85% in 5 years.
STAAR Surgical is the global leader in the market for phakic lenses, which are implanted in the eye to correct vision without removing the natural lens.
The company has recently authorized a $50M buyback, but details on this decision are not provided in the available information.

Generated by AI

STAAR Surgical

Social

Sep 24

Bullish· Apr 9

Bearish· Feb 12

Earnings· May 2

Announcements· Apr 9

Regulars· Apr 9

Newcomers· Sep 24

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday | The Motley Fool

STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know

STAAR Surgical Shares Rise After Stifel Upgrade

STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside - Staar Surgical (NASDAQ

Why is STAAR Surgical stock surging today?

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Staar Surgical (NASDAQ:S

Also Discussed

STAAR Surgical Company

Company Information

Location

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday | The Motley Fool

STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know

STAAR Surgical Shares Rise After Stifel Upgrade

STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside - Staar Surgical (NASDAQ

Why is STAAR Surgical stock surging today?

This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Staar Surgical (NASDAQ:S

Also Discussed

Social

Sep 24

Bullish· Apr 9

Bearish· Feb 12

Earnings· May 2

Announcements· Apr 9

Regulars· Apr 9

Newcomers· Sep 24